| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/10/2013 | CA2561014C Thioamide derivatives as progesterone receptor modulators |
| 09/10/2013 | CA2559038C Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof |
| 09/10/2013 | CA2557758C Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
| 09/10/2013 | CA2551415C Thiazole derivatives and use thereof |
| 09/10/2013 | CA2548308C Phosphatase inhibitor sample collection system |
| 09/10/2013 | CA2548152C Compounds for treatment of cell proliferative diseases |
| 09/10/2013 | CA2539568C Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
| 09/10/2013 | CA2529027C D-amino acid peptides |
| 09/10/2013 | CA2513398C Antisense oligonucleotides that inhibit expression of hif-1 |
| 09/10/2013 | CA2505335C Method of treating movement disorders using barbituric acid derivatives |
| 09/10/2013 | CA2503489C Modulation of zinc levels to improve tissue properties |
| 09/10/2013 | CA2456247C Use of il-18 inhibitors in hypersensitivity disorders |
| 09/10/2013 | CA2451566C Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 09/10/2013 | CA2427340C Cyp1b1 nucleic acids and methods of use |
| 09/10/2013 | CA2281887C Nucleic acid sequences for atp-binding cassette transporter |
| 09/10/2013 | CA2272245C Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies |
| 09/06/2013 | WO2013131105A1 Synergistic anti-proliferation activity of tas-108 with mtor inhibitors against cancer cells |
| 09/06/2013 | WO2013131089A2 Potent anticancer activity via dual compound activation |
| 09/06/2013 | WO2013131040A1 Topical gels containing alpha connexin c-terminal (act) peptides |
| 09/06/2013 | WO2013131018A1 Biaryl inhibitors of the sodium channel |
| 09/06/2013 | WO2013130976A1 Serine/threonine kinase inhibitors |
| 09/06/2013 | WO2013130962A1 Benzofuran- 2 - sulfonamide derivatives as chemokine receptor modulators |
| 09/06/2013 | WO2013130958A1 Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators |
| 09/06/2013 | WO2013130943A1 Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
| 09/06/2013 | WO2013130935A1 Amido-benzyl sulfoxide derivatives |
| 09/06/2013 | WO2013130892A1 Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| 09/06/2013 | WO2013130890A1 Heterobicyclic compounds and their use as phosphodiesterase inhibitors |
| 09/06/2013 | WO2013130855A1 Indazole derivatives |
| 09/06/2013 | WO2013130832A1 Combination therapy for treating androgen deficiency |
| 09/06/2013 | WO2013130811A1 Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists |
| 09/06/2013 | WO2013130775A1 Methods for treating patients undergoing multi-cycle chemotherapy |
| 09/06/2013 | WO2013130767A1 Inhalable dry powders |
| 09/06/2013 | WO2013130766A1 Spray dried formulations |
| 09/06/2013 | WO2013130738A1 Compounds and methods for treating malaria |
| 09/06/2013 | WO2013130725A1 Trioxane thioacetal monomers and dimers and methods of use thereof |
| 09/06/2013 | WO2013130703A2 Binhibitors of hepatitis b virus convalently closed circular dna formation and their method of use |
| 09/06/2013 | WO2013130672A2 Improved cancer treatments and diagnostics |
| 09/06/2013 | WO2013130669A1 Pharmaceutical composition and administration thereof |
| 09/06/2013 | WO2013130660A1 Amides as pim inhibitors |
| 09/06/2013 | WO2013130654A1 Gga and gga derivatives, compositions thereof and methods for treating neurodegenerative diseases including paralysis including them |
| 09/06/2013 | WO2013130603A1 Ganglioside gd2 as a marker and target on cancer stem cells |
| 09/06/2013 | WO2013130600A1 Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith |
| 09/06/2013 | WO2013130577A2 Compositions and methods for the treatment of migraine |
| 09/06/2013 | WO2013130538A2 Method of treating chronic obstructive pulmonary disease |
| 09/06/2013 | WO2013130461A1 Wee1 degradation inhibitors |
| 09/06/2013 | WO2013130422A1 Compositions and methods for treating mitochondrial diseases |
| 09/06/2013 | WO2013130420A1 Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| 09/06/2013 | WO2013130411A1 Salts of potassium atp channel openers and uses thereof |
| 09/06/2013 | WO2013130407A1 Small molecule inhibitors of p-type atpases |
| 09/06/2013 | WO2013130402A1 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt |
| 09/06/2013 | WO2013130370A2 Compounds as dgat-1 inhibitors |
| 09/06/2013 | WO2013130358A1 Macrocyclic compounds |
| 09/06/2013 | WO2013130242A1 Geranylgeranylacetone formulations |
| 09/06/2013 | WO2013130150A2 Metalloporphyrin neurological treatments |
| 09/06/2013 | WO2013130119A1 Method for treating a pulmonary hypertension condition without companion diagnosis |
| 09/06/2013 | WO2013130020A1 Quercetin derivatives, their pharmaceutical composition and use |
| 09/06/2013 | WO2013130013A1 Novel compounds and uses thereof |
| 09/06/2013 | WO2013129944A1 Controlled release compositions and their methods of use |
| 09/06/2013 | WO2013129931A1 Method for improving functional synaptic connectivity |
| 09/06/2013 | WO2013129929A1 Methods for activating retrovirus in latent infected cells, and compounds for use therein |
| 09/06/2013 | WO2013129914A1 Method for improving functional synaptic connectivity |
| 09/06/2013 | WO2013129911A1 Bio-polyols for bio-lubricant and bio-polymer and methods for the preparation thereof |
| 09/06/2013 | WO2013129879A1 Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same |
| 09/06/2013 | WO2013129723A1 Composition for improving skin conditions comprising hordenine |
| 09/06/2013 | WO2013129700A1 Methods and compositions for enhancement of vision performance |
| 09/06/2013 | WO2013128467A1 Ritonavir compositions |
| 09/06/2013 | WO2013128465A1 Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof |
| 09/06/2013 | WO2013128423A1 Use of a glycosylated-modified tetrafunctional non-ionic amphiphilic block copolymer as immune adjuvant |
| 09/06/2013 | WO2013128421A1 Spirohydantoin compounds and their use as selective androgen receptor modulators |
| 09/06/2013 | WO2013128378A1 Phenyl alkanoic acid derivatives as gpr agonists |
| 09/06/2013 | WO2013128037A1 Prodrugs of vitamine k |
| 09/06/2013 | WO2013128029A1 Pharmaceutically active pyrazolo-triazine derivatives |
| 09/06/2013 | WO2013128028A1 Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors |
| 09/06/2013 | WO2013128025A1 Rhogef12 is a therapeutic target for the treatment of heart failure |
| 09/06/2013 | WO2013128000A1 Novel crystalline form of sitagliptin sulfate |
| 09/06/2013 | WO2013127981A1 Protease inhibitors for treating trichomonas gallinae infections |
| 09/06/2013 | WO2013127918A1 New therapeutic approaches for treating parkinson's disease |
| 09/06/2013 | WO2013127917A1 New compositions for treating amyotrophic lateral sclerosis |
| 09/06/2013 | WO2013127913A1 4,4-difluoro-piperidine-compounds |
| 09/06/2013 | WO2013127841A1 Substituted naphthylacetic acids |
| 09/06/2013 | WO2013127831A1 Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| 09/06/2013 | WO2013127830A1 Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant |
| 09/06/2013 | WO2013127828A1 Furo [2, 3 -c] pyridines actives on gpr 119 |
| 09/06/2013 | WO2013127817A1 Imidazole derivatives as pde10a enzyme inhibitors |
| 09/06/2013 | WO2013127728A1 Hormone containing emulsion |
| 09/06/2013 | WO2013127727A1 Hormone containing emulsion comprising krill phospholipids |
| 09/06/2013 | WO2013127361A1 Alkyne-, azide- and triazole-containing flavonoids as modulators for multidrug resistance in cancers |
| 09/06/2013 | WO2013127269A1 Amido spirocyclic amide and sulfonamide derivatives |
| 09/06/2013 | WO2013127268A1 Amido-benzyl sulfone and sulfonamide derivatives |
| 09/06/2013 | WO2013127267A1 Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives |
| 09/06/2013 | WO2013127266A1 Amido-benzyl sulfone and sulfoxide derivatives |
| 09/06/2013 | WO2013127255A1 Process for manufacture of highly enriched extract containing zeaxanthin and/or its esters |
| 09/06/2013 | WO2013127011A1 Reprogramming effector protein interactions to correct epigenetic defects in cancer |
| 09/06/2013 | WO2013126993A1 Screening assays for identifying and validating agents that target cancer stem cells |
| 09/06/2013 | WO2013109213A3 Pharmaceutical formulations comprising tiotropium |
| 09/06/2013 | WO2013106646A3 Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| 09/06/2013 | WO2013082511A9 Methods for overcoming tumor resistance to vegf antagonists |
| 09/06/2013 | WO2013071459A3 Composition comprising a glucocorticoid and a thiazolinedione for inducing complete adipogenic differentiation of mammalian stem cells |
| 09/06/2013 | WO2013059433A3 Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer |
| 09/06/2013 | CA2856552A1 Metalloporphyrin neurological treatments |